Neridronic acid – USA

Neridronic acid – USA

Decision on PGR: Feb 25, 2020

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
FINAL WRITTEN DECISION
PGR2018-00092
08/21/2018
02/25/2019
Grunenthal GmbH
9,820,999
Antecip Bioventures II LLC
Some Challenged Claims Unpatentable
US  9,820,999 (ANTECIP BIOVENTURES II LLC; Exp: May 15, 2034): Non-OB
1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising selecting a human being having CRPS triggered by bone fracture and administering neridronic acid or a pharmaceutically acceptable salt thereof to the human being, wherein the treatment is effective in reducing pain.
Asserted Grounds of Unpatentability:

Claims
35 U.S.C.
Reference(s)/Basis

1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29
102(a)
Varenna 2012
1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29
102(a)
Varenna 2016
1–4, 9, 10, 12, 14, 16–18, 24–25, 27–29
102(a)
Manara
1–4, 9–20, 22–29
103(a)
Varenna 2012, Varenna 2016, Manara, Bruehl
Gatti, La Montagna, and
Muratore
5–8, 21
103(a)
Varenna 2012, Varenna 2016,
Manara, and Manicourt
30
103(a)
Varenna 2012, Varenna 2016
Manara, Schwarzer, Bruehl,
Gatti, La Montagna, and Muratore
1–30
112(a),
Enablement
Order:

It is ORDERED that claims 1–4, 9, 10, 12, 14, 16–18, 23–25, and 27–29 of the ’999 patent are unpatentable;
FURTHER ORDERED that claims 5–8, 11, 13, 15, 19–22, 26, and 30 of the ’999 patent are not shown to be unpatentable.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved